Published: November 06, 2017
Judy’s volunteer work over the past twelve years has evolved into supporting the patient voice in clinical trials research

Judy Needham supporting the patient voice in clinical trials research

The Canadian Cancer Research Alliance (CCRA) has honored members of the research community for their leadership and significant contributions to cancer research in Canada. This year, two new awards have been introduced recognizing exceptional leadership in patient involvement in cancer research.

Published: September 25, 2017
Pancreatic cancer patient Susan Stewart with her family, she enrolled in the CCTG PA.7 immunotherapy and chemotherapy trial

Pancreatic cancer patient Susan Stewart shown here on the right with her family is
enrolled in the CCTG PA.7 immunotherapy and chemotherapy trial

An innovative clinical trial underway across Canada is providing new hope to a B.C. family braving pancreatic cancer – the deadliest cancer facing Canadians today.

Published: September 06, 2017
 Dr Wendy  R.  Parulekar,  Senior  Investigator  at   CCTG
Dr. Wendy R. Parulekar, Senior Investigator MA.39

One of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. A new study undertaken by the Canadian Cancer Trials Group (CCTG) will look at whether additional radiation therapy is beneficial for patients with a specific subtype of breast cancer called luminal A.

Published: August 15, 2017
Dr. Janet Dancey, CCTG Director and JELF award recipient

Dr. Janet Dancey, CCTG Director and JELF award recipient

The Canadian Foundation for Innovation (CFI) John R. Evans Leaders Fund (JELF) has announced a funding award of $197,065 to allow the Canadian Cancer Trials Group (CCTG) to acquire a state-of-the-art digital histology slide scanner.

Published: July 06, 2017

CCTG Participating Sites and Investigators

As you may be aware, the National Clinical Trials Network (NCTN) of the US NCI is planning to launch a new Registration and Credential Repository (RCR) system and a Delegation of Tasks Log (DTL) in the coming months.  These systems are being developed to address requirements for ICH-GCP compliant conduct for NCTN trials, including documentation of qualifications, training, and study specific delegation of tasks.

Published: June 27, 2017
A patient of Dr. Booth’s in the CCTG Challenge Trial

A patient of Dr. Booth’s in the CCTG Challenge Trial follows her exercise prescription.

Clinical trials don’t always set out to prove whether drugs are effective. They can also test surgeries, radiation therapy, or even exercise. Dr. Christopher Booth was a CCTG research fellow in 2006 when results of a 30-year study in the United States noted that the nurses who exercised were less likely to contract colon cancer. Even more interesting was that those who contracted colon cancer and exercised were less likely to relapse. As a colon cancer specialist, Dr.

Published: June 05, 2017
Canadian Cancer Trials Group at the American Society of Clinical Oncology Annual Meeting 2017

It has been another busy year for Canadian Cancer Trials Group at the American Society of Clinical Oncology Annual Meeting. This conference brings together oncology professionals from around the world to discuss state-of-the-art treatments, new therapies with the best minds in the field of cancer research.

CCTG is well represented on this world stage with three recognition awards, fifteen poster presentations, and four oral abstracts. See below for more details.

Published: May 30, 2017
The CCTG Accrual Utility is launched for member sites

The development team from left to right: Corey Willman, Teddy Brown, Patti O'Brien, David Judd, Heather Ritter

The CCTG Accrual Utility Team reached their final project milestone with the official launch of the Accrual Utility late last week. The customized, web-based application was developed by our in-house project team, who worked together to bring this anticipated solution to life.

Published: May 11, 2017
The trial is changing how brain cancer is treated in older patients around the world

Dr Christopher O’Callaghan knows the impact that glioblastoma, an aggressive form of brain cancer, can have on families. His father was diagnosed at a time when the only available treatment was radiation. But now, thanks to Dr O’Callaghan’s research with the Canadian Cancer Trials Group (CCTG), there are better treatment options for patients with glioblastoma.

Published: May 11, 2017
The trial is changing how brain cancer is treated in older patients around the world

Pictured here: Dr Chris O’Callaghan, senior investigator with Dr Janet Dancey, director, Canadian Cancer Trials Group

Dr Christopher O’Callaghan knows the impact that glioblastoma, an aggressive form of brain cancer, can have on families. His father was diagnosed at a time when the only available treatment was radiation. But now, thanks to Dr O’Callaghan’s research with the Canadian Cancer Trials Group (CCTG), there are better treatment options for patients with glioblastoma.